Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 11.89
+0.14 (1.18%)
Sep 4, 2026, 3:03 PM GMT
Fusion Antibodies Market Cap
Fusion Antibodies has a market cap or net worth of 14.71 million as of September 4, 2026. Its market cap has decreased by -23.89% in one year.
Market Cap
14.71M
Enterprise Value
14.84M
Revenue
1.60M
Ranking
n/a
PE Ratio
n/a
Stock Price
11.89
ChartMarket Cap Chart
Since December 18, 2017, Fusion Antibodies's market cap has decreased from 27.28M to 14.71M, a decrease of -46.10%. That is a compound annual growth rate of -6.84%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 4, 2026 | 14.71M | -7.58% |
| Dec 31, 2025 | 15.91M | 135.22% |
| Dec 31, 2024 | 6.76M | 167.72% |
| Dec 29, 2023 | 2.53M | -78.42% |
| Dec 30, 2022 | 11.71M | -59.09% |
| Dec 31, 2021 | 28.62M | -9.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 18, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Hemogenyx Pharmaceuticals | 35.63M |
| Arecor Therapeutics | 27.94M |
| SkinBioTherapeutics | 24.62M |
| ImmuPharma | 21.87M |
| Palatin Technologies | 16.44M |
| IXICO | 16.35M |
| Aptamer Group | 12.09M |
| Genflow Biosciences | 11.89M |